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Pathogenic mechanisms underlying the development of systemic lupus erythematosus (SLE) are very complex and not yet entirely
clariﬁed. However, the pivotal role of T lymphocytes in the induction and perpetuation of aberrant immune response is well
established. Among T cells, IL-17 producing T helper (Th17) cells and regulatory T (Treg) cells represent an intriguing issue to be
addressed in SLE pathogenesis, since an imbalance between the two subsets has been observed in the course of the disease. Treg
cells appear to be impaired and therefore unable to counteract autoreactive T lymphocytes. Conversely, Th17 cells accumulate in
target organs contributing to local IL-17 production and eventually tissue damage. In this setting, targeting Treg/Th17 balance for
therapeutic purposes may represent an intriguing and useful tool for SLE treatment in the next future. In this paper, the current
knowledge about Treg and Th17 cells interplay in SLE will be discussed.
1.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disorder aﬀecting almost all organs and tissues [1, 2]. In
genetically predisposed subjects, environmental factors, such
as viral infections and smoking, induce the breakdown of
self-toleranceeventuallytriggeringautoimmuneresponse[1,
2]. The clinical heterogeneity of the disease often represents
a challenge for clinicians and reﬂects the complexity of
underlying pathogenic mechanisms. The aberrant crosstalk
between diﬀerent immune cells such as B and T lymphocytes
represents a milestone in the natural history of SLE and, in
general terms, of all autoimmune conditions. Self-antigen
presentation by antigen presenting cells may be identiﬁed
as the primum movens that leads to recruitment, activation,
and expansion of autoreactive lymphocytes. This cascade
culminates with disease-speciﬁc autoantibody production
by B cells and eventually with target tissue injury [1–3]. B
lymphocytes are well-recognized actors in SLE pathogenesis,
and this is further conﬁrmed by the eﬀectiveness of B-
cell depleting therapies in these patients [4]. Moreover, an
altered T-cell homeostasis which plays a pivotal role in the
development of the disease and the longstanding paradigm
of T helper (Th) 1/Th2 cell immune response was recently
challenged by the recognition of Th17 cells and regulatory
T cells (Treg) [5, 6]. This intriguing evidence pointed out
the need to call into question previous discoveries. The
aim of this paper is to discuss the current knowledge
about the interplay between Treg and Th17 cells in the
pathogenesis of SLE and potential therapeutic intervention
in this setting.
2.Th17 CellSubsetsinSLE
Th17 cells were identiﬁed according to their capability to
produce IL-17, and initially they were thought to be just
a variant of Th1 cells and to origin from a common
precursor [5, 7]. Nonetheless, further investigation ruled
out this possibility and found that Th17 commitment of
na¨ ıve T cells, by the expression of STAT-3 and retinoic acid
orphan receptor-(ROR-) γt, was attributable to the presence
of both transforming growth factor-(TGF) β a n dI L - 6i nt h e
surrounding microenvironment [8–12].2 Clinical and Developmental Immunology
First cloned in 1995, IL-17 family cytokines display
a broad spectrum of action including the capacity to
induce the production of inﬂammatory and tissue-damaging
molecules.
In particular, IL-17A is able to stimulate the produc-
tion of chemokines and cytokines from multiple cells like
epithelial cells and ﬁbroblasts [13] and to promote the
proliferation, maturation, and recruitment of neutrophils,
macrophages, and lymphocytes through the induction of
colony-stimulating factors and chemokines [13].
Concerning IL-17 in SLE, recent data from humans and
mice clearly support the role of this cytokine and Th17
cells in lupus pathogenesis. To note, it has been observed by
several groups that SLE patients, including those with new-
onset disease, had increased serum or plasma levels of IL-
17, expansion of IL-17-producing T cells in the peripheral
blood, and inﬁltration of Th17 cells in target organs like
the kidneys [14–20]. Some studies showed that circulating
IL-17 levels correlate with disease activity [14–17]a n d
are associated with kidney involvement [20]. In addition,
increased expression of IL-17 and RORγtm R N Ah a sb e e n
found in urine sediments from lupus patients [21]. Taken
together, these results point out the pivotal role played by
IL-17 in mediating target organ damage in both early and
long-standing stages of the disease [22].
Notably, the involvement of IL-17 in the perpetuation of
lupus nephritis was recently underlined by the elegant study
performed by Crisp´ ın et al., in which a novel pathogenic
Th17 cell subset was identiﬁed [23]. This small T-cell pop-
ulation, named double negative (DN) according to the lack
of both CD4 and CD8 molecules expression, appeared to be
responsible for most of IL-17 production in sera and kidney
of SLE patients. This may be explained by the hypothesis that
a l lD NTc e l l sa r ea l r e a d yc o m m i t t e din vivo towards a Th17
phenotype, whereas CD4+ cells require additional stimuli to
diﬀerentiate into IL-17 producing T cells. Interesting, IL-17
can also promote humoral immunity that plays a major role
in lupus pathogenesis. IL-17, alone or in combination with
B-cell activating factor (BAFF), increases the survival and
proliferation of human B cells as well as the diﬀerentiation of
B cells into antibody-producing cells [12, 24]. In conclusion,
IL-17 could promote inﬂammation in lupus by aﬀecting
both cellular and humoral immune response. In this setting,
additional studies are needed to ﬁnd out the mechanisms for
increased Th17 cell response and the therapeutic implication
of targeting IL-17 in SLE, as discussed in detail below.
3.Treg-CellSubsetsinSLE
The other face of the coin in the pathogenesis of SLE is
represented by Treg cells [25]. Since their ﬁrst identiﬁcation
in late 90s, Treg cells became a hot topic in immunology
because of the recognition of a link between impairment
of this cell population and development of autoimmunity
[6, 26–29]. Indeed, Treg cells display suppressive activity
towards autoreactive lymphocytes thus preventing the onset
of aberrant self-immune response [30]. Initially, Treg-cells
were isolated in humans and mice according to high surface
levels of CD25 (IL-2Rα) and intracellular expression of
the forkhead winged helix (Fox) P3 transcription factor.
FoxP3 expression is required for commitment of Treg cells
and maintenance of their functional activity [31]. To date,
several Treg cell subsets have been identiﬁed. They diﬀer
from each other for either phenotypic features or origin.
Natural Treg cells (nTreg) are produced in the thymus in
the very early phases of life following an appropriate T-
cell receptor (TCR) stimulation and in the presence of a
peculiar cytokine microenvironment. Conversely, inducible
Treg cells (iTreg) result from the diﬀerentiation of na¨ ıve T
cells in secondary lymphoid organs during the entire life [32,
33]. However, this classiﬁcation appears slightly restrictive
nowadays,sincedeeperunderstandingofTregcellphysiology
has been achieved. Our group and other investigators
observed that T cells lacking CD25 and expressing FoxP3
displayed suppressive activity towards eﬀector T cells from
both healthy subjects and pathological conditions [34–37]
Interestingly,weprovidedthecluethatthesurfaceexpression
of glucocorticoid-induced tumor necrosis factor receptor
family-related protein (GITR) on CD25− T cells was able
to confer them a regulatory phenotype and function [34].
In addition, as will be discussed in detail below, iTreg
cells may originate from activated T cells when appropriate
stimuli are present in the surrounding microenvironment
[38]. Abnormalities of this ﬁne tuning may result in the
development of autoimmunity.
In recent years, Treg-cell assessment in SLE has been
performed by several groups [39]. Unfortunately, although
much eﬀort has been spent to shed some light on Treg
imbalance in SLE, conclusive data are still lacking [40]. The
majority of these studies reported either reduced number or
impaired function of circulating Treg cells in SLE [41–44].
On the opposite, others failed to observe any abnormalities
in this T-cell subset and found resistance of eﬀector T
c e l l st or e g u l a t o r ya c t i v i t yo fT r e gc e l l s[ 45, 46]. These
discrepancies may arise from fair diﬀerences between iso-
lation protocols and ﬂow-cytometry technicalities resulting
in strong diﬃculties in comparing results from diﬀerent
studies. Moreover, data regarding Treg cells in SLE target
organs, such as kidney, are poor, and, hence, regulatory
mechanisms controlling Treg homeostasis within aﬀected
tissues are still a matter of debate [47, 48]. According to
theaforementioneddataregardingputativeTregcellslacking
CD25, Zhang et al. recently evaluated circulating CD25− T
cells in SLE patients and surprisingly found an increase of
the CD25−FoxP3+ fraction [49]. Further analysis, however,
allowed to conclude that this cell subpopulation was actually
divergent from conventional Treg cells, as they failed to
exert suppressive activity in vitro towards CD25−FoxP3−
eﬀectorTcells[50].Inthissetting,albeitFoxP3isuniversally
accepted as speciﬁc marker of Treg cells, it must be taken
into account that in some cases its expression may be
misinterpreted. Noteworthy, it has been recently suggested
that, besides the expression itself, FoxP3 intensity is the
true discriminator between eﬀector and regulatory T cells.
Indeed, FoxP3low T cells often produced IL-2 independently
on CD25 surface levels, whereas FoxP3high T cells did not
[51]. Furthermore, we demonstrated that among the CD25−Clinical and Developmental Immunology 3
cell subset, only those coexpressing GITR on the surface
display in vitro suppressive activity that can be reverted by
antibody-mediated GITR blockade [34]. In conclusion, the
deﬁnite role of Treg-cells in SLE is still uncertain and further
studies are required to shed some light on this controversial
issue. At the same time, the identiﬁcation of more speciﬁc
phenotypic Treg cell markers in an attempt to minimize
variability between diﬀerent studies are surely needed.
4. The InterplaybetweenTh17 andTreg Cellsin
SLE:Who’s Who?
Besides the above-mentioned diﬃculty to clarify the eﬀective
role played by Th17/Treg cells in SLE pathogenesis, recent
studies made this matter even more complex providing the
clue of a plasticity between the two T-cell subsets [38]. As
suggested by Lee et al., it appeared that TGF-β plays a dual
role on na¨ ıve T cells depending on the presence or absence
of IL-6. The combination of TGF-β and IL-6 allows the
diﬀerentiation toward a Th17 phenotype, whereas if TGF-
β is present alone, iTreg cells will be generated [10, 11,
52]. Furthermore, transition between Th17 and Th1 cells
may also be possible. Indeed, several groups have generated
Th17 cells in vitro and adoptively transferred to induce
autoimmune disease in mice. After transfer in vivo, Th17
cells quickly acquire the ability to produce IFN-γ,a sT h 1
cells do, and lose their capacity to release IL-17 [53, 54].
A similar behavior was observed in vitro following several
culture rounds. It has been proposed that the shift from
Th17 to Th1 cell may be due, at least in part, to the fact
that Th17 cells express IL-12 receptors and readily produce
IFNγ in response to IL-12 exposure [55]. In addition, also an
epigenetic mechanism may underlie the plasticity of CD4+ T
helper cell diﬀerentiation, as recently suggested [56].
These ﬁndings draw our attention to new intriguing
scenarios in which the cytokine milieu is the key player
that globally drives immune response towards either health
or disease [57]. However, it has been already described
that SLE ﬂares may occur as a consequence of cytokine
imbalance and eventually of the Th17/Treg ratio in lupus-
prone mice [8]. More recently, it has been demonstrated
that such imbalance is not limited to SLE ﬂares but is
hallmark of the disease, since also patients with quiescent
disease display a Th17/Treg ratio favoring Th17 cells [58,
59]. Taken together, these evidences prompt therapeutic
approaches aimed to restore an adequate cytokine network
and Th17/Treg balance in SLE. Indeed, although Th17 cells
play a key role in the pathogenesis of the disease, Th1 and
other eﬀector cells are also involved in the perpetuation
of autoimmune response [14, 60–63]. Therefore, selective
Th17 targeting may not be suﬃcient to counteract chronic
inﬂammation in SLE patients. On the other hand, restoring
the immune balance between Th17 and Treg cells may help
to achieve a better clinical response. These observations are
strengthened by the evidence that selective Th17 blockade
led to disease worsening in a murine model of colitis and
exacerbated acute graft-versus-host disease, reasonably for a
rebound increase of Th1 cells [64, 65]. In this context, it is
noteworthy that previous studies have conﬁrmed the ability
of some agents, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), rapamycin, and the vitamin A metabolite all-trans-
retinoic acid, to promote the conversion of Th17 to Treg
cells in experimental autoimmune encephalomyelitis [66–
68]. It is to note, however, that TCDD is toxic in animals and
humans, while all-trans-retinoic acid and rapamycin have
not been yet tested in humans. Moreover, the nucleosomal
histonepeptideepitopeH471-94appearstobeabletoinduce
generation of Treg cells and suppression of inﬂammatory
Th17 cells in lupus-prone mice, through the induction of
tolerogenic dendritic cells rather than via a direct eﬀect on
Treg/Th17 cells [69].
In conclusion, the aforementioned data suggest that
targetingTh17andTregcellsfortherapeuticpurposesinSLE
may be possible. However, further investigations aimed to
identify well-tolerated and powerful compounds that induce
the diversion of T-cell diﬀerentiation from Th17 cells to Treg
cells are needed [70, 71].
5. Conclusions
Aberrant T-cell homeostasis is a crucial event in SLE
pathogenesis, and Th17/Treg imbalance appears to represent
an important key pathogenic player. However, many aspects
of such a deregulation in the course of the disease are still
uncertain, and conclusive data about speciﬁc underlying
mechanisms are lacking. Promising results concerning ther-
apeutic targeting Th17/Treg cell balance may open new lines
of investigation for SLE treatment in the near future.
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